Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00037518
Recruitment Status : Completed
First Posted : May 20, 2002
Last Update Posted : May 8, 2013
Information provided by:

Brief Summary:
This study will assess an investigational medication for patients with severe primary hyperparathyroidism or parathyroid cancer.

Condition or disease Intervention/treatment Phase
Hyperparathyroidism Parathyroid Neoplasms Drug: AMG 073 Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 46 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Assessment of the Calcimimetic Agent AMG 073 for the Treatment of Subjects With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism.
Study Start Date : April 2001

Primary Outcome Measures :
  1. Changes in serum calcium and PTH

Secondary Outcome Measures :
  1. Safety and tolerability of cinacalcet

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
  • Patients must have parathyroid carcinoma or severe primary hyperparathyroidism; * Abnormally elevated calcium levels above 12.5 mg/dL; * Not be pregnant or nursing; * Not have had any type of cancer other than parathyroid carcinoma within the last 5 years.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00037518

Sponsors and Collaborators
Layout table for investigator information
Study Director: MD Amgen
Additional Information:
Publications of Results:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Global Development Leader, Amgen Inc. Identifier: NCT00037518    
Other Study ID Numbers: 20000204
First Posted: May 20, 2002    Key Record Dates
Last Update Posted: May 8, 2013
Last Verified: May 2013
Keywords provided by Amgen:
Severe primary hyperparathyroidism
Parathyroid carcinoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Parathyroid Neoplasms
Hyperparathyroidism, Primary
Parathyroid Diseases
Endocrine System Diseases
Endocrine Gland Neoplasms
Neoplasms by Site
Head and Neck Neoplasms
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Calcimimetic Agents
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists